Jason Lettmann is a General Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical and medical technology sectors. Jason also is a General Partner on the Life Science team at Morgenthaler Ventures and brings over 15 years of operating and venture experience in the life sciences. He currently serves on the Board of Directors of ALX Oncology, Carrick Therapeutics, Cerevance, FIRE1, Relievant Medsystems, and Second Genome. Jason served as the CEO of Promedior and led the company through its sale to Roche in 2020 as well as led the firm’s investments and served as a Director of Ra Pharmaceuticals (acquired by UCB) and Vapotherm (NASDAQ: VAPO). Jason also established Lightstone’s Europe office in 2014 located in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd.
Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in the life sciences. During his time at Split Rock, Jason was actively involved with the firm’s investment in Ardian (acquired by Medtronic), Cabochon Aesthetics (acquired by Ulthera), Atritech (acquired by Boston Scientific), Entellus Medical (acquired by Stryker), Evalve (acquired by Abbott), and Transcend Medical (acquired by Alcon). Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013.